Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of etrolizumab versus infliximab in TNF inhibitor-naive moderate to severe ulcerative colitis
MOH_2017-07-20_000653Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrolizumab active + infliximab-matching placebo with Infliximab active + etrolizumab-matching placebo (2 arms). Started Nov 2014; status: recruiting.
02
Drugs
Etrolizumabinfliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-07-20_000653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-20_000653.